title: Window of opportunity for daclizumab.
authors.forename: Kimberly S
authors.initials: KS
authors.lastname: Schluns
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D017951:Antigen Presentation / Q000187:drug effects; D000077561:Daclizumab; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000378:metabolism; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D018448:Models, Immunological; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508594:IL2 protein, human; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; D000077561:Daclizumab